Drug Trial Radar · NCT06703346
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Dec 31, 2019
Primary completion
Mar 1, 2024
Study completion Jul 24, 2026
Sponsor
- Lead sponsor
- USWM CT, LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Conditions
- Neoplasms
Interventions
Letetresgene autoleucel (Lete-Cel (GSK3377794))Drug
Letetresgene autoleucel will be administered
CyclophosphamideDrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy
FludarabineDrug
Fludarabine will be used as a lymphodepleting chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (Overall Response Rate)Time frame: Up to approximately 36 months
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Stanford Hospital and Clinics
Stanford, California
Sarah Cannon Research Institute
Denver, Colorado
Mayo Clinic Jacksonville
Jacksonville, Florida
University of Chicago
Chicago, Illinois
University of Iowa College of Medicine
Iowa City, Iowa
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Minnesota Oncology Hematology
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Washington University
St Louis, Missouri
Memorial Sloan Kettering cancer center
New York, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University-Columbus
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pittsburgh, Hillman Cancer centre
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
University Of Texas Southwestern Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
University of Utah
Salt Lake City, Utah
Virginia Commonwealth University
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Froedtert Hospital
Milwaukee, Wisconsin
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CIUSSS de L'Est-De-Lile-De-Montreal
Montreal, Quebec, Canada
Centre Léon Bérard
Lyon, France
CHU de Bordeaux GH Sud Hôpital Haut Lévêque
Pessac, France
Fondazione IRCCS Instituto Nazionale Dei Tumori
Milan, Lombardy, Italy
Ircss Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
The Netherlands Cancer Institute
Amsterdam, Netherlands
Hospital Santa Creu Y Sant Pau
Barcelona, Spain
Ico Duran y Reynals l'Hospitalet de Llobrega
Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Virgen Del Rocio
Seville, Spain
Royal Marsden Hospital
London, United Kingdom
University College Hospital-London
London, United Kingdom
Christie Hospital NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.